Literature DB >> 17651015

Transforming growth factor-beta signaling in normal and malignant hematopoiesis.

Iris Isufi1, Mahesh Seetharam, Li Zhou, Davendra Sohal, Joanna Opalinska, Perry Pahanish, Amit Verma.   

Abstract

Transforming growth factor-beta (TGF-beta) is an important physiologic regulator of cell growth and differentiation. TGF-beta has been shown to inhibit the proliferation of quiescent hematopoietic stem cells and stimulate the differentiation of late progenitors to erythroid and myeloid cells. Insensitivity to TGF-beta is implicated in the pathogenesis of many myeloid and lymphoid neoplasms. Loss of extracellular TGF receptors and disruption of intracellular TGF-beta signaling by oncogenes is seen in a variety of malignant and premalignant states. TGF-beta can also affect tumor growth and survival by influencing the secretion of other growth factors and manipulation of the tumor microenvironment. Recent development of small molecule inhibitors of TGF-beta receptors and other signaling intermediaries may allow us to modulate TGF signaling for future therapeutic interventions in cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17651015     DOI: 10.1089/jir.2007.0009

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  25 in total

1.  Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.

Authors:  Catharina Wenk; Anne-Kathrin Garz; Sonja Grath; Christina Huberle; Denis Witham; Marie Weickert; Roberto Malinverni; Julia Niggemeyer; Michèle Kyncl; Judith Hecker; Charlotta Pagel; Christopher B Mulholland; Catharina Müller-Thomas; Heinrich Leonhardt; Florian Bassermann; Robert A J Oostendorp; Klaus H Metzeler; Marcus Buschbeck; Katharina S Götze
Journal:  Blood Adv       Date:  2018-12-11

2.  Aryl hydrocarbon receptor-null allele mice have hematopoietic stem/progenitor cells with abnormal characteristics and functions.

Authors:  Kameshwar P Singh; Russell W Garrett; Fanny L Casado; Thomas A Gasiewicz
Journal:  Stem Cells Dev       Date:  2010-11-09       Impact factor: 3.272

3.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

Authors:  Thomas Clozel; ShaoNing Yang; Rebecca L Elstrom; Wayne Tam; Peter Martin; Matthias Kormaksson; Samprit Banerjee; Aparna Vasanthakumar; Biljana Culjkovic; David W Scott; Sarah Wyman; Micheal Leser; Rita Shaknovich; Amy Chadburn; Fabrizio Tabbo; Lucy A Godley; Randy D Gascoyne; Katherine L Borden; Giorgio Inghirami; John P Leonard; Ari Melnick; Leandro Cerchietti
Journal:  Cancer Discov       Date:  2013-08-16       Impact factor: 39.397

4.  Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma.

Authors:  Shudan Mao; Wenqi Yang; Limei Ai; Zhe Li; Jieping Jin
Journal:  Tumour Biol       Date:  2015-07-14

5.  Targeting Smad4 links microRNA-146a to the TGF-beta pathway during retinoid acid induction in acute promyelocytic leukemia cell line.

Authors:  Hua Zhong; Hai-rong Wang; Shuang Yang; Ji-hua Zhong; Ting Wang; Chun Wang; Fang-yuan Chen
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

6.  Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice.

Authors:  David Caudell; David P Harper; Rachel L Novak; Rachel M Pierce; Christopher Slape; Linda Wolff; Peter D Aplan
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

7.  Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.

Authors:  Kyoko Takeuchi; Masahiro Abe; Masahiro Hiasa; Asuka Oda; Hiroe Amou; Shinsuke Kido; Takeshi Harada; Osamu Tanaka; Hirokazu Miki; Shingen Nakamura; Ayako Nakano; Kumiko Kagawa; Kenichiro Yata; Shuji Ozaki; Toshio Matsumoto
Journal:  PLoS One       Date:  2010-03-25       Impact factor: 3.240

8.  In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.

Authors:  Anmaar M Abdul-Nabi; Enas R Yassin; Nobish Varghese; Hrishikesh Deshmukh; Nabeel R Yaseen
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

9.  Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

Authors:  Li Zhou; Aaron N Nguyen; Davendra Sohal; Jing Ying Ma; Perry Pahanish; Krishna Gundabolu; Josh Hayman; Adam Chubak; Yongkai Mo; Tushar D Bhagat; Bhaskar Das; Ann M Kapoun; Tony A Navas; Simrit Parmar; Suman Kambhampati; Andrea Pellagatti; Ira Braunchweig; Ying Zhang; Amittha Wickrema; Satyanarayana Medicherla; Jacqueline Boultwood; Leonidas C Platanias; Linda S Higgins; Alan F List; Markus Bitzer; Amit Verma
Journal:  Blood       Date:  2008-05-12       Impact factor: 22.113

10.  Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.

Authors:  Ailing Lu; Manuel A Pallero; Weiqi Lei; Huixian Hong; Yang Yang; Mark J Suto; Joanne E Murphy-Ullrich
Journal:  Am J Pathol       Date:  2016-01-20       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.